L.E.L. Hendriks

Brunetti, L., Colella, G., Di Fazio, G. R., La Cava, G., Santo, V., Pecci, F., Rotow, J. K., Bauman, J. R., Nassar, A. H., Adib, E., Naqash, A. R., Tagliamento, M., Ferrara, R., Citarella, F., Russano, M., Ricciuti, B., Faivre-Finn, C., Hendriks, L. E. L., Passaro, A., ... Cortellini, A. (2026). First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology, 21(8), Article 103735. https://doi.org/10.1016/j.jtho.2026.103735

Sugden, B. M., Witlox, W. J. A., Cortiula, F., Hendriks, L. E. L., van Loon, J., Jacobs, M., Hattu, D., Joore, M. A., Ramaekers, B. L. T., & De Ruysscher, D. K. M. (2026). Assessing the impact of proton versus photon therapy on health-related quality of life in lung cancer. Clinical and Translational Radiation Oncology, 59, Article 101160. https://doi.org/10.1016/j.ctro.2026.101160

Ortega-Franco, A., Houda, I., Brandao, M., Pierret, T., Kaesmann, L., Giaj-Levra, N., Remon, J., Berghmans, T., Dingemans, A.-M. C., Faivre-Finn, C., & Hendriks, L. E. L. (2026). Upfront management of brain metastases in oncogene-addicted NSCLC - An EORTC survey. Lung Cancer, 217, Article 109444. https://doi.org/10.1016/j.lungcan.2026.109444

Zullo, L., Bortolot, M., Ogliari, F. R., Saw, S. P. L., van Geel, R., ter Heine, R., Sadowska, A., Remon, J., & Hendriks, L. (2026). Antibody-Drug Conjugates in Non-small Cell Lung Cancer. Drugs, 86(7), 1045-1073. https://doi.org/10.1007/s40265-026-02331-z

Saw, S. P. L., Li, M. S. C., Park, S., Hatano, H., Uehara, Y., Menis, J., Brandão, M., Hendriks, L. E. L., & Remon, J. (2026). Targeting Met In Egfr-Mutated Nsclc. Journal of Thoracic Oncology, 21(7), Article 103711. https://doi.org/10.1016/j.jtho.2026.103711

Remon, J., La-Cava, G., Borgeaud, M., Saw, S. P. L., Hendriks, L. E. L., & Ricciuti, B. (2026). KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians. Cancer Treatment Reviews, 147, Article 103144. https://doi.org/10.1016/j.ctrv.2026.103144

Willmann, J., Dee, E. C., Hendriks, L. E. L., Dimitriou, N. M., Jongbloed, M., Schoenfeld, A. J., Drilon, A., Ganesh, K., Zhang, Y. H., Feldman, J., Werner, R., Opitz, I., Carrot-Zhang, J., Schultz, N., Veeraraghavan, H., Jones, D. R., Awad, M., Rudin, C. M., Popat, S., ... Iyengar, P. (2026). Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies. Journal of Clinical Oncology, 44(16), 1540-1552. https://doi.org/10.1200/JCO-25-01958

McMahon, R. A., Lee Min Chua, K., Faivre-Finn, C., Filippi, A. R., Hendriks, L. E. L., John, T., Liu, S. V., McDonald, F., Popat, S., Saw, S. P. L., Munoz-Schuffenegger, P., Velcheti, V., Louie, A. V., & Siva, S. (2026). Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee. Journal of Thoracic Oncology, 21(6), Article 103643. https://doi.org/10.1016/j.jtho.2026.103643

Riess, J. W., Yu, H. A., Le, X., de Langen, A. J., Cho, B. C., Piotrowska, Z., Hendriks, L. E. L., Morabito, A., Bonanno, L., Brustugun, O. T., Halvorsen, T. O., Kim, Y. J., Marrone, K. A., Shiraishi, Y., Goldman, J. W., Ambrose, H., Smith, P. E., FraenkeI, P. G., Tang, K. H., ... Goldberg, S. B. (2026). Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD. Annals of Oncology, 37(6), 825-836. https://doi.org/10.1016/j.annonc.2026.02.014

Lanser, D. A. C., Heersche, N., Muntinghe-Wagenaar, M. B., Ali, M. I. M., Ulas, E. B., de Jonge, E., Oomen-de Hoop, E., Paats, M. S., Bahce, I., Croes, S., Langen, A. J., Hendriks, L. E. L., Wekken, A. J., Huitema, A. D. R., Schaik, R. H. N., Dingemans, A.-M. C., Veerman, G. D. M., & Mathijssen, R. H. J. (2026). Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer. Cancer Communications, 46, Article 0031. https://doi.org/10.34133/cancomm.0031